Teresa R. Zembower

Teresa R. Zembower

Auto-generated profile, based on publicly available information

Teresa R. Zembower

Northwestern University , Chicago, Illinois

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2014
Verified
Book Chapter
Closed access
PDF file
TZTeresa R. Zembower
Teresa R. Zembower

1 January 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SRScott C Roberts
Scott C Roberts
TZTeresa R Zembower
Teresa R Zembower

13 October 2015 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
IEI.A. Echenique
I.A. Echenique
VSV. Stosor
V. Stosor
LGL. Gallon
L. Gallon
DKD. Kaufman
D. Kaufman
CQC. Qi
C. Qi
TZT.R. Zembower
T.R. Zembower

1 March 2010 in Emerging Infectious Diseases
Verified
Journal Article
Open access
ABAmanda L. Bonebrake
Amanda L. Bonebrake
CSChristina Silkaitis
Christina Silkaitis
GMGaurav Monga
Gaurav Monga
AGAmy Galat
Amy Galat
JAJay Anderson
Jay Anderson
TZTeresa R. Zembower
Teresa R. Zembower
In 2006, nearly 6,000 mumps cases were reported in the United States, 795 of which occurred in Illinois. In Chicago, 1 healthcare institution experienced ongoing transmission for 4 weeks. This study examines the outbreak epidemiology and quantifies the financial affect on this organization. This retrospective cohort study was conducted through case and exposure identification, interviews, medical record reviews, and immunologic testing of blood specimens. Nine mumps cases resulted in 339 exposures, 325 (98%) among employees. During initial investigation, 186 (57%) of the exposed employees had evidence of mumps immunity. Physicians made up the largest group of noncompliers (55%) with mumps immunity testing. The cost to the institution was $262,788 or $29,199 per mumps case. The outbreak resulted in substantial staffing and financial challenges for the institution that may have been minimized with readily accessible electronic employee vaccination records and adherence to infection control recommendations.

7 June 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TZTeresa R. Zembower
Teresa R. Zembower
KMKelly M. Maxwell
Kelly M. Maxwell
RNRobert B. Nadler
Robert B. Nadler
JCJohn Cashy
John Cashy
MSMarc Scheetz
Marc Scheetz
ASAnthony J. Schaeffer
Anthony J. Schaeffer
We evaluated the effectiveness of targeted antimicrobial prophylaxis in transrectal ultrasound guided prostate biopsy (TRUSP). A prospective, non-randomized cohort study was conducted. Rectal swab cultures plated on non-selective blood agar and on selective MacConkey agar supplemented with ciprofloxacin identified ciprofloxacin-susceptible and –resistant gram-negative bacteria (CS-GNB and CR-GNB). Patients with CS-GNB received ciprofloxacin while those with CR-GNB received directed prophylaxis. Infectious complications were defined clinically and microbiologically within 30 days after TRUSP. Data were derived at 7 and 30 days post procedure by questionnaires and electronic medical records. We hypothesized that there would be no difference in the infectious outcomes among the CS and CR groups. From November 1, 2012 to March 31, 2015, 510 men completed the study; 430 (84.3%) had CS-GNB and 80 (15.7%) had CR-GNB. 484 (94.9%) completed the study per protocol, while 26 (5.1%) had an intention-to-treat (ITT) analysis. Of the 484, 475 (98.1%) had no infections, nine (1.9%) had infections, six of which (1.2%) were culture-proven (CP). The nine infections were as follows: five (1.0%) uncomplicated UTIs, one (0.2%) complicated UTI, and three (0.6%) urosepsis. One case of uncomplicated UTI and two cases of urosepsis were not CP, but were diagnosed clinically. ITT outcomes were similar. The infection rates were not statistically different between the CS-and CR-GNB patients (p-value = 0.314; 95% CI 0.8–3.3). The four patients with complicated UTIs or sepsis were hospitalized for a mean of 2.6 days and discharged without sequelae. Of the nine infections, three were antimicrobial prophylaxis failures (two ciprofloxacin and one amikacin); three were likely due to failure of the collection or processing of the rectal swab or increasing bacterial resistance between the time of swab collection and biopsy, and three developed clinical infections with no isolate recovered. Targeted antimicrobial prophylaxis follows the principles of antimicrobial stewardship and achieved a low rate of infectious complications with limited morbidity and no sequelae. This individualized method of prophylaxis may be widely applied. Further studies are needed to explore reasons for targeted prophylaxis failure and to determine comparative efficacy of non-ciprofloxacin-containing targeted prophylaxis regimens. ClinicalTrials.gov. NCT01659866 . Registered 9 July 2012. First patient enrolled 1 November 2012.

27 December 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
CECharlesnika T. Evans
Charlesnika T. Evans
BDBenjamin J. DeYoung
Benjamin J. DeYoung
EGElizabeth L. Gray
Elizabeth L. Gray
AWAmisha Wallia
Amisha Wallia
JHJoyce Ho
Joyce Ho
JWJohn T. Wilkins
John T. Wilkins
Objectives: Healthcare workers (HCWs) are a high-priority group for coronavirus disease 2019 (COVID-19) vaccination and serve as sources for public information. In this analysis, we assessed vaccine intentions, factors associated with intentions, and change in uptake over time in HCWs.Methods: A prospective cohort study of COVID-19 seroprevalence was conducted with HCWs in a large healthcare system in the Chicago area. Participants completed surveys from November 25, 2020, to January 9, 2021, and from April 24 to July 12, 2021, on COVID-19 exposures, diagnosis and symptoms, demographics, and vaccination status.Results: Of 4,180 HCWs who responded to a survey, 77.1% indicated that they intended to get the vaccine. In this group, 23.2% had already received at least 1 dose of the vaccine, 17.4% were unsure, and 5.5% reported that they would not get the vaccine. Factors associated with intention or vaccination were being exposed to clinical procedures (vs no procedures: adjusted odds ratio [AOR], 1.39; 95% confidence interval [CI], 1.16–1.65) and having a negative serology test for COVID-19 (vs no test: AOR, 1.46; 95% CI, 1.24–1.73). Nurses (vs physicians: AOR, 0.24; 95% CI, 0.17–0.33), non-Hispanic Black (vs Asians: AOR, 0.35; 95% CI, 0.21–0.59), and women (vs men: AOR, 0.38; 95% CI, 0.30–0.50) had lower odds of intention to get vaccinated. By 6-months follow-up, >90% of those who had previously been unsure were vaccinated, whereas 59.7% of those who previously reported no intention of getting vaccinated, were vaccinated.Conclusions: COVID-19 vaccination in HCWs was high, but variability in vaccination intention exists. Targeted messaging coupled with vaccine mandates can support uptake.